Sorrento Therapeutics, Inc., a late-stage clinical oncology company developing new treatments for cancer and associated pain, reports that its fully owned subsidiary, Igdrasol has acquired exclusive distribution rights from Samyang Biopharmaceuticals, a South Korean corporation, to Cynviloq (marketed as Genexol-PM in South Korea) in South America.

Sorrento’s most advanced asset, Cynviloq, is a nanoparticle paclitaxel, under clinical development. Sorrento is also developing resiniferatoxin (RTX), a non-opiate TRPV1 agonist currently in a Phase I/II study at the National Institutes of Health to treat terminal cancer patients suffering from intractable pain.

In December 2014, the company and NantWorks formed a global joint venture, now called Nantibody, to focus on certain immunotherapies for cancer and autoimmune diseases. The company and Conkwest, Inc., a privately held immuno-oncology company developing proprietary Neukoplast, a Natural Killer (NK) cell-line based therapy, also entered into an agreement to jointly develop next generation CAR.TNK (Chimeric Antigen Receptor Tumor-attacking Neukoplast) immunotherapies for the treatment of cancer. The CAR.TNK technology platform combines Conkwest’s proprietary Neukoplast cell line with Sorrento’s proprietary G-MAB fully human antibody technology and CAR designs to further enhance the potency and targeting of Neukoplast. More recently, in March 2015, Sorrento entered into a global collaboration with NantCell, a NantWorks company, to discover and develop novel anti-cancer immunotherapies.

Source: Sorrento